by the patient after the outer layer has disintegrated or has dissolved intraorally; and

(c) a pharmaceutically acceptable signaling system located between the first portion and second portion of the composition, within the first portion of the composition or within the second portion of the composition and that is detectable by the patient upon substantial release of the butorphanol tartrate capable of intraoral administration during intraoral administration thereby informing the patient that it is time to orally ingest the remaining second part of the composition containing the rofecoxib capable of oral administration. --

**REMARKS**

This amendment is submitted in order to be responsive to the Examiner's requirement for restriction and for election of species.

In response to the requirement for restriction, Applicants provisionally elect the claims of Group I. In response to the requirement of election of species, Applicants are submitting new claim 32 as the elected species claim. Antecedent basis for new claim 32 may be found in the specification in the examples on pages 32 through 36. Claims 1 through 3, 5 through 19 and 22 through 28 are all readable on the elected species of claim 32.

Applicants traverse the requirement for restriction between the pharmaceutical composition claims and the method of administration claims. The restriction requirement between the